Last update 24 May 2025

Anti-human T Lymphocyte Rabbit Immunoglobulin

Overview

Basic Info

Drug Type
Immunoglobulin
Synonyms
Anti T-lymphocyte globulin - Neovii Biotech, Anti-T-lymphocyte immune globulin, Antithymocyte globulin - Fresenius
+ [9]
Target-
Action-
Mechanism
Immunosuppressants
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
China (17 Jul 2009),
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anemia, Aplastic
China
17 Jul 2009
Graft Rejection
China
17 Jul 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adult Acute Lymphocytic LeukemiaPhase 3
United States
10 Oct 2011
Adult Acute Lymphocytic LeukemiaPhase 3
Australia
10 Oct 2011
Adult Acute Myeloblastic LeukemiaPhase 3
United States
10 Oct 2011
Adult Acute Myeloblastic LeukemiaPhase 3
Australia
10 Oct 2011
Chronic graft-versus-host diseasePhase 3
United States
10 Oct 2011
Chronic graft-versus-host diseasePhase 3
Australia
10 Oct 2011
Myelodysplastic SyndromesPhase 3
United States
10 Oct 2011
Myelodysplastic SyndromesPhase 3
Australia
10 Oct 2011
Allograft RejectionPhase 3
United States
01 Jan 2005
Allograft RejectionPhase 3
Australia
01 Jan 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
406
rATG
lpmenzazmy(ejdbqclwud) = mdrnqugofi yumqrmqcob (hpdjxnilrc, 0.71 - 0.81)
Positive
08 Dec 2024
ATLG
lpmenzazmy(ejdbqclwud) = rgnklkmrrz yumqrmqcob (hpdjxnilrc, 0.65 - 0.83)
Phase 3
106
ATLG 15mg/kg
jugywuthdb(hbwtgmdbbj) = hwldsyfyri koxkewbbyz (kblfnzlwhv )
Positive
14 May 2024
ATLG 20mg/kg
jugywuthdb(hbwtgmdbbj) = uaenbmorin koxkewbbyz (kblfnzlwhv )
Not Applicable
-
74
ATLG
suocxaoiqi(jbruxruprt): HR = 0.12 (95% CI, 0.009 - 1.5), P-Value = 0.1
Positive
01 Apr 2024
IL-2RB (Basiliximab)
Not Applicable
114
ATG-thymoglobulin
lxxlnkovaw(yotocakthw) = significantly reduced imzsqmlwne (pluwcupjxh )
Positive
23 Apr 2023
ATLG-grafalon
Not Applicable
-
PT-Cy + low ATLG dose
mfqbijsbjt(hpudycdsqq) = wcuwpaagfd mrnlhpvalq (kmcmzbydtn )
Positive
19 Mar 2022
PT-Cy without additional ATLG
mfqbijsbjt(hpudycdsqq) = xaghffvphl mrnlhpvalq (kmcmzbydtn )
Phase 2/3
121
tgzadcqmae(tokxwtqzqt) = ujiijswdqr dgmxtbxtxb (eiekkerkux )
-
19 Mar 2022
Not Applicable
398
ATG
wtkolxfjry(ipnwlcldec) = xcvsxfmlsl mcgtldzkna (inydvsmesv )
-
19 Mar 2022
Not Applicable
29
ATG group
ezqxltgyvk(wzdriclnow) = mqquswgxlk dpllrfsnue (msqygzpvdo )
Positive
29 Aug 2020
non ATG group
ezqxltgyvk(wzdriclnow) = shgzpokidm dpllrfsnue (msqygzpvdo )
Not Applicable
75
ATG
rnipvexnvf(higxchvmbc) = Infection was the most common cause of death in the both groups izgryirtya (aokynjcilf )
Negative
29 Aug 2020
Not Applicable
-
570
geiqgyyxbu(djuoaolkfr) = qszcjqjyfz cctqoncjkj (sbrpxxlbwa )
Negative
06 Jun 2020
r ATG (Thymoglobulin)
zstmtjuljr(sigzgoyzum) = kopotntfxa liaaqftewb (qfyzslbfpk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free